Apixaban, commonly known as Eliquis, is a widely prescribed anticoagulant used to prevent blood clots in patients with conditions like deep vein thrombosis (DVT), pulmonary embolism, or atrial fibrillation, where clotting can increase the risk of stroke. Determining the ideal duration of apixaban treatment is essential to ensure both safety and effectiveness. Factors such as individual health conditions, age, and kidney function influence both the recommended dosage and the length of time apixaban is used. Patients and healthcare providers must also consider potential side effects, ways to handle missed doses, and any contraindications in planning long-term anticoagulation therapy with it.
Key Takeaways
The length of apixaban treatment varies by individual, depending on specific health conditions such as DVT, pulmonary embolism, or atrial fibrillation. Some patients may need short-term therapy, while others require long-term or even lifelong treatment.
- Dosage may differ based on factors like age, kidney function, and the specific condition being treated, with typical doses including 2.5 mg or 5 mg taken twice daily.
- While effective in preventing blood clots, apixaban may carry risks like bleeding; monitoring and regular consultation with a healthcare provider help manage these risks.
- If a dose is missed, it’s crucial to follow proper guidance on resuming treatment to avoid potential clotting risks.
- Apixaban may not be suitable for individuals with severe kidney or liver conditions, active bleeding disorders, or other specific health concerns.
- Patients and healthcare providers should regularly review the need for ongoing apixaban therapy to ensure it remains safe and beneficial over time.
How Long Should You Be on Apixaban?
The duration for which a patient should remain on apixaban depends on the specific condition being treated. For individuals with nonvalvular atrial fibrillation, the typical recommendation is to take 5 mg twice daily indefinitely, as long as the risk of stroke remains. In cases of deep vein thrombosis (DVT) or pulmonary embolism (PE), it is usually prescribed for an initial treatment period of at least 3 months, after which the duration may be extended based on individual risk factors and clinical judgment.
Studies suggest that extended treatment can last up to 12 months or longer if there is a high risk of recurrence and no significant bleeding risks are present. For patients undergoing hip or knee replacement surgery, it is typically administered for 12 to 35 days post-surgery, depending on the type of surgery. Patients must consult their healthcare provider regarding the appropriate duration of therapy based on their specific medical history and risk factors, as stopping apixaban suddenly can increase the risk of thromboembolic events.
What Does Apixaban Do to the Heart?
Apixaban primarily functions as an anticoagulant to reduce the risk of blood clots and strokes, particularly in patients with atrial fibrillation. By inhibiting factor Xa, it decreases thrombin levels, which in turn reduces the formation of fibrin and platelet aggregation, thereby preventing clot formation.
While apixaban is effective in lowering thromboembolic events, studies indicate that it does not significantly influence cardiac remodeling or improve heart function after myocardial infarction.
For instance, research has shown that apixaban did not alter left ventricular ejection fraction or other markers of cardiac hypertrophy in animal models of heart failure following a heart attack. Therefore, while it plays a crucial role in preventing complications related to clotting disorders, its direct effects on heart function and remodeling are limited, suggesting that it should not be relied upon to treat underlying cardiac conditions.
One user shared their experience on Reddit, saying, “I took Eliquis as part of my pre-ASCT induction therapy. I’d never had a blood clot previously, and it worked well for me, completely getting rid of the headaches I used to experience several days a week.”
When Should Apixaban Be Stopped?
When considering when to stop apixaban, several clinical scenarios and guidelines should be taken into account. Here’s the key considerations:
Before Surgery or Invasive Procedures
- Elective Surgery: It should generally be discontinued 2 to 3 days before elective surgery or invasive procedures to minimize bleeding risks. For procedures with a higher risk of bleeding, a longer discontinuation period of up to 5 days may be warranted, especially in patients with renal or hepatic impairment.
- Low-Risk Procedures: For surgeries with a low risk of significant bleeding, they can be stopped at least 24 hours before the procedure.
Active Bleeding
- In cases of active pathological bleeding, apixaban should be stopped immediately. Standard supportive measures should be taken, and local interventions may be necessary.
Switching Anticoagulants
- When transitioning from apixaban to another anticoagulant (e.g., warfarin), it is crucial to manage the timing properly to avoid gaps in anticoagulation that could lead to thrombotic events. Generally, apixaban should be stopped when the INR is below 2.0 if switching to warfarin.
Risks Associated with Discontinuation
Stopping apixaban can significantly increase the risk of thrombotic events, including stroke and systemic embolism, particularly in patients with non-valvular atrial fibrillation. Therefore, if discontinuation is necessary for reasons other than bleeding, bridging with another anticoagulant may be advisable.
Special Considerations
- Patients with impaired renal function may require more cautious management regarding the timing of apixaban discontinuation due to increased bleeding risks associated with renal dysfunction.
- Individual risk factors such as age, weight, and history of thromboembolic events should guide decisions on when to stop it.
How Long Is It Safe to Take Apixaban?
The duration for which apixaban can be safely taken varies based on the underlying condition being treated.
Atrial Fibrillation
- Patients with non-valvular atrial fibrillation may require long-term or even lifelong treatment with it to reduce the risk of stroke and systemic embolism. The decision to continue therapy should be based on individual risk factors and clinical judgment.
Venous Thromboembolism (VTE)
- For patients who have experienced a deep vein thrombosis (DVT) or pulmonary embolism (PE), it is typically prescribed for at least 3 months. Depending on the recurrence risk, some patients may need to continue treatment for a longer duration.
Post-Surgical Prophylaxis
- After orthopedic surgeries such as knee or hip replacements, the duration of apixaban therapy is generally:
- Knee Replacement- 10 to 14 days
- Hip Replacement- 32 to 38 days
Apixaban Side Effects
While it offers significant benefits in reducing the risk of stroke and thromboembolic events, it also carries the potential for various side effects. Here’s a comprehensive overview of the side effects associated with it:
Common Side Effects
- Bleeding
- Gastrointestinal Symptoms
- Fatigue and Weakness
- Dizziness or Light-headedness
Serious Side Effects
- Severe Bleeding
- Spinal/Epidural Hematoma
- Allergic Reactions
What Are the Long-Term Effects of Taking Apixaban?
The long-term effects of taking it, an oral anticoagulant, can be significant in both positive and negative aspects. Here’s a detailed overview based on current research and clinical findings.
Positive Long-Term Effects
Reduced Risk of Thromboembolic Events
Apixaban has been shown to effectively reduce the risk of stroke and systemic embolism in patients with atrial fibrillation. In studies, the annual rate of stroke or systemic embolism was approximately 1.0% to 1.1% during long-term treatment, indicating its efficacy in preventing these serious complications.
Management of Venous Thromboembolism (VTE)
For patients with a history of VTE, apixaban significantly lowers the risk of recurrence. In clinical trials, the rate of recurrent VTE was markedly lower in patients receiving apixaban compared to those on placebo, showcasing its effectiveness for extended treatment.
Lower Rates of Major Bleeding
Long-term use of apixaban is associated with relatively low rates of major bleeding events, reported at about 1.2% per year. This is particularly favorable compared to traditional anticoagulants like warfarin, which often require more intensive monitoring and management due to higher bleeding risks.
Negative Long-Term Effects
Bleeding Risks
While the rates are low, the risk of bleeding remains a significant concern with long-term use. Patients may experience minor bleeding (e.g., easy bruising, nosebleeds) or more severe events (e.g., gastrointestinal bleeding). Serious bleeding complications can occur but are less frequent compared to other anticoagulants.
Potential for Spinal Hematoma
There is a risk of developing a blood clot around the spinal cord (spinal hematoma), particularly in patients undergoing spinal procedures such as epidurals or spinal taps. This can lead to long-term or permanent paralysis if not managed promptly.
Kidney Function Monitoring
Long-term use may necessitate regular monitoring of kidney function, as apixaban is partially eliminated through the kidneys. Impaired renal function can increase the risk of bleeding and necessitate dosage adjustments
Apixaban 2.5 mg vs. 5 mg
It is typically available in two dosages: 2.5 mg and 5 mg. The prescribed dose depends on the condition being treated, as well as individual factors like age, weight, and kidney function.
- Apixaban 5 mg– This is the standard dose for most adult patients, particularly those with atrial fibrillation or who have experienced a clotting event. This dose provides effective clot prevention while maintaining a balance between clotting and bleeding risks.
- Apixaban 2.5 mg– This lower dose is generally prescribed to elderly patients or those with compromised kidney function, who may be at a higher risk of bleeding complications. It may also be used as a preventative dose after initial treatment for DVT or pulmonary embolism to reduce recurrence risk.
A healthcare provider will determine the most appropriate dose based on an individual’s needs and health factors, ensuring that the medication remains effective while minimizing side effects.
Apixaban Dose in Elderly
When prescribing apixaban for elderly patients, careful consideration of dosage is crucial due to age-related changes in pharmacokinetics and an increased risk of side effects. For most adults aged 18 to 79 years, the typical dosage of apixaban is 5 mg taken twice daily. However, for patients aged 80 years or older, or those who weigh 60 kg (132 lbs) or less, or have a serum creatinine level of 1.5 mg/dL or higher, the recommended dose is reduced to 2.5 mg taken twice daily. This adjustment is essential to mitigate the increased risk of bleeding associated with anticoagulants in this population.
Several factors influence these dosage adjustments. Renal function is particularly important, as elderly patients often experience decreased renal function, leading to higher plasma concentrations of it and an increased risk of bleeding. Regular assessment of renal function is vital, and dosage adjustments should be made accordingly. Additionally, body weight plays a significant role; patients weighing less than 60 kg are also considered for a lower dose due to their heightened risk for adverse effects from standard doses.
Comorbidities must also be taken into account when determining the appropriate dosage. The presence of other health conditions, such as liver dysfunction or concurrent medications that may interact with it, can further influence dosing decisions. Regular monitoring for signs of bleeding and renal function is critical in elderly patients on apixaban to ensure safety and effectiveness
Apixaban Dose for DVT
For the treatment of deep vein thrombosis (DVT) and pulmonary embolism, the standard dosing approach typically involves a higher initial dose, followed by a maintenance dose. For instance:
- Initial Dose: Patients often begin with 10 mg twice daily for the first seven days.
- Maintenance Dose: After this period, the dose is reduced to 5 mg twice daily.
The initial higher dose helps break down clots and prevent their spread, while the maintenance dose keeps the blood’s clotting ability in check over time. For some patients, a reduced 2.5 mg dose may be considered long-term to prevent recurrence after the initial treatment phase, especially if they have risk factors for bleeding.
Apixaban Contraindications
Contraindications refer to conditions or factors that make the use of a medication like apixaban inappropriate because it could lead to serious or even life-threatening complications.
Active Bleeding Disorders
Patients with active bleeding, such as gastrointestinal bleeding or bleeding within the brain, should not take apixaban. Since apixaban works by preventing blood clots, it could worsen these conditions, leading to excessive blood loss and potential emergencies.
Severe Liver Impairment
Apixaban is metabolized in the liver, so patients with severe liver impairment, particularly those with liver disease associated with coagulopathy, should avoid it. In these cases, liver dysfunction might reduce the body’s ability to process apixaban, increasing the risk of bleeding.
Prosthetic Heart Valves
Apixaban is not recommended for patients with mechanical heart valves. Studies indicate that the risks of clotting and bleeding are increased in such cases, so these patients are typically managed with other anticoagulants like warfarin, which has been studied more extensively in this population.
Renal Impairment
Although apixaban can be adjusted for patients with mild to moderate kidney dysfunction, it’s contraindicated in severe cases of renal impairment or for patients undergoing dialysis. Since impaired kidney function reduces the drug’s clearance from the body, this can lead to dangerously high concentrations of the medication and elevate bleeding risks.
History of Hypersensitivity to Apixaban
If a patient has experienced an allergic reaction to apixaban or any of its components, they should not use this medication. Signs of hypersensitivity can range from skin rashes to anaphylaxis, and alternative anticoagulants should be considered.
Pregnancy and Breastfeeding
While not explicitly contraindicated, the use of apixaban is generally discouraged in pregnant or breastfeeding individuals due to insufficient data on its safety for these groups. The potential risks to the fetus or infant may outweigh the benefits of anticoagulation, and safer options may be available.
Concomitant Use with Other Anticoagulants
Taking apixaban with other anticoagulants, such as heparin, enoxaparin, or warfarin, is usually contraindicated due to the increased risk of bleeding. Combined anticoagulation therapy is generally avoided unless strictly necessary under medical supervision, as it can dramatically raise the likelihood of serious bleeding events.
What Happens if You Miss a Dose of Apixaban?
If you miss a dose of apixaban, it is important to take the missed dose as soon as you remember, provided that it is still more than 6 hours until your next scheduled dose. If it is less than 6 hours until your next dose, you should skip the missed dose and continue with your regular dosing schedule. It is crucial not to double up on doses to make up for a missed one, as this could increase the risk of bleeding complications.
The anticoagulant effects of apixaban can begin to wear off within approximately 24 hours, which means that missing multiple doses in succession can significantly elevate the risk of thromboembolic events, such as stroke or deep vein thrombosis (DVT). Therefore, adherence to the prescribed dosing schedule is essential for maintaining effective anticoagulation.
In case you accidentally take more than the prescribed dose of apixaban, it is advisable to contact your healthcare provider or seek emergency medical attention immediately, as this can also lead to serious bleeding risks. Regular communication with healthcare professionals regarding any missed doses or concerns about medication adherence is essential for safe management while on apixaban therapy.
Final Thought
Apixaban, a widely used anticoagulant, is invaluable in managing blood clot risks, particularly for patients dealing with atrial fibrillation, deep vein thrombosis (DVT), or pulmonary embolism (PE). By working to prevent clots from forming in the bloodstream, apixaban reduces the risk of severe complications such as strokes, which are commonly associated with these conditions. The specific duration a patient should be on apixaban varies and depends significantly on their unique health profile and risk factors.
For some, the treatment may be lifelong, particularly for chronic conditions, while others might only need it temporarily to prevent clots during high-risk periods or post-surgery. This makes it essential for patients to engage in consistent follow-ups with healthcare providers to ensure that their apixaban dosage and duration are optimized for safety and effectiveness.
Exploring options to buy Apixaban from Canada can offer significant savings and accessibility, particularly for those requiring long-term anticoagulation therapy.
We are a reliable source that dispenses authentic Apixaban and other medications through our affiliated Canadian dispensing pharmacy which is licensed in Manitoba, Canada.
